接种BNT162b2和mRNA-1273后新型冠状病毒2型抗体反应的比较
Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273.
作者信息
Steensels Deborah, Pierlet Noella, Penders Joris, Mesotten Dieter, Heylen Line
机构信息
Ziekenhuis Oost-Limburg, Genk, Belgium.
出版信息
JAMA. 2021 Oct 19;326(15):1533-1535. doi: 10.1001/jama.2021.15125.
Abstract
This study compares the immune responses to the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines in health care workers in Belgium.
摘要
本研究比较了比利时医护人员对BNT162b2（辉瑞-生物科技公司）和mRNA-1273（莫德纳公司）两种新冠疫苗的免疫反应。
相似文献
1
Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273.接种BNT162b2和mRNA-1273后新型冠状病毒2型抗体反应的比较
JAMA. 2021 Oct 19;326(15):1533-1535. doi: 10.1001/jama.2021.15125.
2
Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?接受BNT162b2 mRNA疫苗或AZD1222疫苗的健康志愿者中针对SARS-CoV-2的中和抗体反应比较：AZD1222疫苗的第二剂是否应提前接种？
Am J Hematol. 2021 Sep 1;96(9):E321-E324. doi: 10.1002/ajh.26248. Epub 2021 Jun 2.
3
Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.评估新冠疫苗需要标准化的中和抗体检测。
EBioMedicine. 2021 Nov;73:103677. doi: 10.1016/j.ebiom.2021.103677. Epub 2021 Nov 3.
4
Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.BNT162b2 和 mRNA-1273 两种 SARS-CoV-2 疫苗接种后的 IgG 抗体反应差异。
Microbiol Spectr. 2021 Dec 22;9(3):e0116221. doi: 10.1128/Spectrum.01162-21. Epub 2021 Nov 10.
5
Spike Antibody Titers Evaluation after a 2-Dose Regimen of BNT162b2 Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2.在先前感染过SARS-CoV-2的医护人员中，接种两剂BNT162b2疫苗后的刺突抗体滴度评估。
Microbiol Spectr. 2021 Dec 22;9(3):e0103621. doi: 10.1128/Spectrum.01036-21. Epub 2021 Nov 10.
6
Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.韩国医护人员接种第二剂 BNT162b2 mRNA 疫苗 6 个月后仍保持对 SARS-CoV-2 的抗体应答。
Front Immunol. 2022 Jan 31;13:827306. doi: 10.3389/fimmu.2022.827306. eCollection 2022.
7
Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.有或无前新冠病毒感染启动的情况下，SARS-CoV-2疫苗BNT162b2的抗体依赖性中和能力
J Intern Med. 2021 Dec;290(6):1272-1274. doi: 10.1111/joim.13366. Epub 2021 Aug 2.
8
Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.在先前感染过 SARS-CoV-2 的医护人员中，单次接种 ChAdOx1 nCoV-19 疫苗后的抗体反应。
EBioMedicine. 2021 Aug;70:103523. doi: 10.1016/j.ebiom.2021.103523. Epub 2021 Aug 12.
9
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局：一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
10
mRNA SARS-CoV-2 Immunization Confers Robust Antibody Response in Occupational Healthcare Workers and Fosters Workplace Safety.mRNA新冠病毒免疫在职业医护人员中引发强劲抗体反应并促进工作场所安全。
J Occup Environ Med. 2021 May 1;63(5):e314-e317. doi: 10.1097/JOM.0000000000002187.
引用本文的文献
1
Recurrent waning of anti-SARS-CoV-2 neutralizing antibodies despite multiple antigen encounters.尽管多次接触抗原，但抗SARS-CoV-2中和抗体仍反复减弱。
J Transl Med. 2025 Jul 11;23(1):783. doi: 10.1186/s12967-025-06837-0.
2
Exploring the COVID-19 Vaccine: New Onset and Exacerbations in Rheumatic Diseases.探索新冠疫苗：风湿性疾病的新发与病情加重情况
Cureus. 2025 Apr 14;17(4):e82249. doi: 10.7759/cureus.82249. eCollection 2025 Apr.
3
Risk of new-onset seizures following immunization against COVID-19: a self-controlled case-series study.接种新型冠状病毒肺炎疫苗后新发癫痫的风险：一项自我对照病例系列研究。
Epidemiol Health. 2025;47:e2025024. doi: 10.4178/epih.e2025024. Epub 2025 May 2.
4
Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.美国成人中原始单价新冠疫苗基础免疫系列随时间推移的有效性。
PLoS One. 2025 May 6;20(5):e0320434. doi: 10.1371/journal.pone.0320434. eCollection 2025.
5
Impact of Extended Dosing Intervals and Ipsilateral Versus Contralateral Boosting on mRNA Vaccine Immunogenicity in Mice.延长给药间隔以及同侧与对侧加强免疫对小鼠mRNA疫苗免疫原性的影响
Vaccines (Basel). 2025 Mar 1;13(3):263. doi: 10.3390/vaccines13030263.
6
Multipronged strategy for protection and motivation of healthcare workers during the COVID-19 pandemic: a real-life study.新冠疫情期间医护人员保护与激励的多管齐下策略：一项实际研究
Antimicrob Steward Healthc Epidemiol. 2024 Jul 25;4(1):e101. doi: 10.1017/ash.2023.459. eCollection 2024.
7
IPNA clinical practice recommendations on care of pediatric patients with pre-existing kidney disease during seasonal outbreak of COVID-19.国际儿科肾脏病学会（IPNA）关于新冠病毒病（COVID-19）季节性暴发期间患有基础肾脏病的儿科患者护理的临床实践建议
Pediatr Nephrol. 2025 May;40(5):1795-1815. doi: 10.1007/s00467-024-06565-5. Epub 2024 Dec 29.
8
SARS-CoV-2 Immunization Index in the Academic Community: A Retrospective Post-Vaccination Study.学术界的SARS-CoV-2免疫指数：一项疫苗接种后的回顾性研究。
Infect Dis Rep. 2024 Nov 25;16(6):1084-1097. doi: 10.3390/idr16060088.
9
Features of chronic urticaria after COVID-19 mRNA vaccine over time.新冠mRNA疫苗接种后慢性荨麻疹随时间变化的特征
Commun Med (Lond). 2024 Nov 30;4(1):254. doi: 10.1038/s43856-024-00656-y.
10
Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France.在法国，免疫功能低下的患者接种了针对变异株的改良 mRNA COVID-19 疫苗后，疾病的临床和经济负担大大减轻。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2423474. doi: 10.1080/21645515.2024.2423474. Epub 2024 Nov 14.
Zotero 插件